Q-omics provides the consensus-scored GABARAPL3 profile across patient tissues and cancer cell-line models. Additionally, GABARAPL3 RNA expression shows 2 significant drug associations, with the highest sampling consensus in PEMB_ALL.

Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.

Premium analyses for GABARAPL3 — synthetic lethality, tumor antigen, and pembrolizumab response.

View premium →

Cross-omics associations

This table shows molecular features associated with GABARAPL3 in patient tissues and cancer cell lines. In patient samples, GABARAPL3 shows the broadest associations at the RNA and protein expression levels, with PEMB_ALL recurring as the lineage with the largest associated feature set. In cancer cell lines, GABARAPL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.

Associated data type	Strength (# associated data)	Lineage of highest associated data
▼RNA
Drug	2	PEMB_ALL (1)	view →

Associated data type	Strength (# associated data)	Lineage of highest associated data
▼shRNA
shRNA	1,552	SKIN (344)	view →
RNA	1,388	PANCREAS (257)	view →
▼Mutation
Mutation	366	LARGE_INTESTINE (366)	view →
▼RNA
Inducing drug	2	NCI60_ALL (2)	view →